Skip to content
Costs

How Much Does a Biotech Patent Cost in 2026?

MadePatents Research Team | Last updated April 5, 2026

Pricing data last verified: April 2026

Biotech patent cost breakdown guide

Biotech patents cost $10,000 to $20,000+ for a non-provisional application, with our research showing an average of approximately $9,900 across patent professionals who handle biotech IP. Total cost from filing through grant runs $18,000 to $40,000+ because biotech applications face more office action rounds and require more specialized prior art analysis than most other categories.

Biotech is the most expensive patent category after pharmaceutical. The specifications are long, often running 50 to 100+ pages. Claims must be drafted with precision because biotech examiners scrutinize enablement and written description requirements closely. And the prior art landscape spans not just patents but scientific journals, gene databases, and international filings.

Cost Breakdown by Biotech Category

Invention TypeExamplesAttorney FeesUSPTO FeesTotal Through Grant
Diagnostic methodBiomarker test, point-of-care assay, genetic screening method$8,000 to $14,000$800 to $2,000$14,000 to $22,000
Composition/formulationNovel drug formulation, vaccine adjuvant, biologic composition$12,000 to $20,000$1,000 to $2,500$20,000 to $32,000
Therapeutic methodGene therapy protocol, immunotherapy approach, drug delivery method$14,000 to $22,000+$1,000 to $3,000$22,000 to $38,000+
Research tool/processLab assay, purification method, cell culture technique, sequencing method$8,000 to $14,000$800 to $2,000$12,000 to $22,000

These ranges include typical office action responses. They do not include maintenance fees, which add $3,365 to $13,460 over the patent’s 20-year life.

For baseline costs, see our full patent cost guide.

What Drives Biotech Patent Costs

Specification length. Biotech specifications are among the longest of any patent category. The enablement requirement under 35 U.S.C. 112 demands that you describe the invention in enough detail that someone skilled in the field could reproduce it without undue experimentation. For biological inventions, that often means including experimental protocols, sequence data, and results demonstrating that the invention actually works.

Written description scrutiny. Biotech examiners apply the written description requirement more strictly than examiners in other fields. If your claims cover a genus (e.g., “a class of antibodies that bind to target X”), the specification must demonstrate that you actually possessed the full scope of what you are claiming. Generic descriptions without supporting data get rejected.

Sequence listings. Patents involving DNA, RNA, or protein sequences must include formal sequence listings following USPTO rules. The formatting requirements are specific and the listings can add significant length to the application. Some applications include dozens or hundreds of sequences.

Extended prosecution. Biotech applications go through more office action rounds on average. The examiner may raise issues under Sections 101 (patent eligibility for natural phenomena), 102/103 (novelty/obviousness over scientific literature), and 112 (enablement and written description). Each round costs $1,500 to $5,000 to respond. Budget for 2 to 4 rounds. See our guide on office actions.

Specialized prior art. Biotech prior art extends far beyond the patent database. Examiners search PubMed, GenBank, UniProt, and scientific journals. Your attorney must be familiar with these databases to anticipate what the examiner will find and draft claims that distinguish your invention from published research.

Provisional Filing for Biotech Inventions

A provisional patent for a biotech invention costs $4,000 to $6,000 on average based on our research. This is above the overall average because biotech provisionals must include enough experimental detail and sequence data to support the eventual non-provisional claims.

The provisional is critical in biotech because academic publications and conference presentations can destroy patent rights. If you plan to publish research or present at a conference, file the provisional first. Any public disclosure starts the 12-month filing deadline, and most countries outside the US have no grace period at all.

Full guide: Provisional Patent Cost

Patentability After Myriad and Mayo

Two Supreme Court decisions shape what is patentable in biotech:

Association for Molecular Pathology v. Myriad Genetics (2013): Naturally occurring DNA sequences are not patentable. But synthetic DNA (cDNA), modified proteins, and engineered biological molecules remain patentable. The line is whether the claimed molecule exists in nature as-is.

Mayo Collaborative Services v. Prometheus Labs (2012): Methods that simply observe a natural correlation (e.g., measuring a biomarker level and correlating it to a condition) may not be patentable. But methods that include a specific treatment step, a novel measurement technique, or an unconventional combination of steps can clear the bar.

These decisions add cost because the attorney must draft claims that clearly fall on the patentable side of these lines. Generic claims that cover natural phenomena get rejected under Section 101.

How to Reduce Biotech Patent Costs

File provisionals strategically. Use provisionals to lock in filing dates as experimental results come in. You can file multiple provisionals and consolidate them into one non-provisional within 12 months of the earliest filing. This is common in biotech where results develop over time.

Qualify as a micro entity. Academic researchers, small startups, and solo inventors often qualify for 75% USPTO fee discounts. See small business patent costs.

Hire someone with life science expertise. Biotech patent prosecution requires understanding the science. An attorney with a PhD or extensive experience in your specific subfield will draft stronger claims and respond to office actions more effectively. Use the MadePatents directory to filter by biotech specialty.

Start with the most commercially valuable invention. If you have multiple inventions, patent the one with the clearest commercial application first. This focuses your budget where it has the most business impact. Read our guide on patent strategy for startups.

Find a Biotech Patent Attorney

The MadePatents directory includes patent professionals across all 50 states who handle biotech patent applications. Use the specialty filter to find practitioners with life science backgrounds, then compare pricing, reviews, and credentials.

Use our patent cost calculator to estimate total filing costs based on your invention’s complexity.

Frequently Asked Questions

How much does a biotech patent cost?

A biotech patent costs $10,000 to $20,000+ for the non-provisional application, with an average around $9,900 based on our research across patent professionals. Total cost through grant runs $18,000 to $40,000+ including office action responses.

Why are biotech patents more expensive than mechanical patents?

Biotech patents require longer specifications with experimental data, sequence listings, and detailed method descriptions. They face more office actions on average and the prior art analysis is more complex because it spans scientific literature, gene databases, and international patent filings.

Can I patent a gene or protein sequence?

You cannot patent naturally occurring genes or proteins (per the 2013 Myriad decision). But you can patent synthetic DNA sequences, modified proteins, methods of using biological molecules, diagnostic methods based on biomarkers, and novel formulations. The key is that the claimed invention must involve human intervention beyond isolating what nature already created.

How long does it take to get a biotech patent?

Biotech patents take 2.5 to 4+ years from filing to grant. The examination process is longer because examiners review scientific literature and databases in addition to patent prior art. Complex applications may go through 3 to 5 rounds of office actions.